Dmitry I. Trukhan , Dmitry A. Kalinichenko
Abstract
The issue of urinary incontinence is multidisciplinary. Such patients present to general practitioners, pediatricians, urologists, gynecologists, neurologists. Often, it is a first-contact physician (primary care provider, general practitioner) that patients come to with this delicate problem, if there is a trusting relationship between the physician and the patient. The review reports topical aspects of the clinical features, diagnosis, and treatment of urge urinary incontinence (overactive bladder) at the outpatient stage. M-anticholinergics currently represent the “gold standard” of drug therapy of incontinence associated with the detrusor overactivity. However, concerns have emerged in recent years that M-anticholinergics also can block M1and M2 receptors in the brain. These receptors are responsible for high cognitive functioning, and abnormalities of those can result in side effects associated with learning, memory, and confusion. Trospium chloride, the quaternary amine, is almost unable to cross the blood-brain barrier, in contrast to tertiary amines; it is considered as a drug of choice for treatment of overactive bladder, especially in patients with comorbidities and elderly patients at risk of dementia. The analysis of the trospium chloride pharmacokinetics and pharmacodynamics has made it possible to determine a number of other trospium chloride advantages over tertiary amines.
Keywords: urinary incontinence, overactive bladder, clinical features, diagnosis, treatment, M-anticholinergics, trospium chloride.
Keywords: urinary incontinence, overactive bladder, clinical features, diagnosis, treatment, M-anticholinergics, trospium chloride.
About the Author
Dmitry I. Trukhan 1 , Dmitry A. Kalinichenko 11 Omsk State Medical University, Omsk, Russia
References
1. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных синдромов и симптомов при заболеваниях почек и мочевых путей. М.: Практическая медицина, 2019. https: //www.litres.ru/dmitriy-truhan/differencialnyy-diagnoz-osnovnyh-sindromov-i-simpt-55287956
Trukhan D.I., Filimonov S.N. Differential diagnosis of the main syndromes and symptoms in diseases of the kidneys and urinary tract. Moscow: Practical medicine, 2019. https: //www.litres.ru/dmitriy-truhan/differencialnyy-diagnoz-osnovnyh-sindromov-i-simpt-55287956 (in Russian).
2. Клинические рекомендации. Недержание мочи. 2024. Одобрено Научно-практическим советом Минздрава России.
Clinical recommendations. Urinary incontinence. 2024. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. https://cr.minzdrav.gov.ru/recomend/8_2 (in Russian).
3. Трухан Д.И., Юренев Г.Л., Чусова Н.А. Недержание мочи: актуальные аспекты клиники, диагностики и лечения на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019;(1):52-61.
Trukhan D.I., Yurenev G.L., Chusova N.A. Urinary incontinence: topical aspects of the clinic, diagnosis and treatment at the stage of primary health care. The directory of the polyclinic doctor. 2019;(1):52-61 (in Russian).
4. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. DOI: 10.1002/nau.10052
5. Abrams P, Cardozo L, Fall M et al. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61(1):37-49. DOI: 10.1016/s0090-4295(02)02243-4
6. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int 2001;87(9):760-6. DOI: 10.1046/j.1464-410x.2001.02228.x
7. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36. DOI: 10.1007/s00345-002-0301-4
8. Irwin DE, Milsom I, Hunskaar S et al. Incontinence. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019
9. Stenzelius K, Mattiasson A, Hallberg IR, Westergren A. Symptoms of urinary and faecal incontinence among men and women 75+ in relations to health complaints and quality of life. Neurourol Urodyn 2004;23(3):211-22. DOI: 10.1002/nau.20030
10. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных симптомов и синдромов при заболеваниях почек и мочевых путей. Уч. пособие. Новокузнецк: Полиграфист, 2018.
Trukhan D.I., Filimonov S.N. Differential diagnosis of the main symptoms and syndromes in diseases of the kidneys and urinary tract. A study guide. Novokuznetsk: Polygraphist, 2018. (in Russian).
11. Трухан Д.И., Тарасова Л.В., Быстрова Д.А. Диагностический и лечебный алгоритм при недержании мочи. Справочник поликлинического врача. 2013;(6):39-41. www.elibrary.ru/item.asp?id=21810788
Trukhan D.I., Tarasova L.V., Bystrova D.A. Diagnostic and therapeutic algorithm for urinary incontinence. The directory of the polyclinic doctor. 2013;(6):39-41. www.elibrary.ru/item.asp?id=21810788 (in Russian).
12. Трухан Д.И., Быстрова Д.А., Романов Н.А. Недержание мочи: актуальные аспекты клиники, диагностики и лечения. Справочник поликлинического врача. 2014;(9):54-9. www.elibrary.ru/item.asp?id=23417380
Trukhan D.I., Bystrova D.A., Romanov N.A. Urinary incontinence: topical aspects of the clinic, diagnosis and treatment. The directory of the polyclinic doctor. 2014;(9):54-9. www.elibrary.ru/item.asp?id=23417380 (in Russian).
13. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021;(9):11-23. DOI: 10.47407/kr2021.2.9.00103
Trukhan D.I., Chuyanova Yu.S., Makushin D.G. The problem of urinary incontinence through the prism of comorbidity. Clinical review for general practice. 2021;(9):11-23. DOI: 10.47407/kr2021.2.9.00103 (in Russian).
14. Akbar A, Liu K, Michos ED et al. Association of overactive bladder with hypertension and blood pressure control: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 2022;35(1):22-30. DOI: 10.1093/ajh/ hpaa186
15. Garvey WT, Garber AJ, Mechanick JI et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014;20(9):977-89. DOI: 10.4158/EP14280.PS
16. Furukawa S, Sakai T, Niiya T et al. Microvascular complications and prevalence of nocturia in Japanese patients with type 2 diabetes mellitus: The Dogo study. Urology 2016;(93):147-51. DOI: 10.1016/j.urology.2016.03.017
17. Furukawa S, Sakai T, Niiya T et al. Macrovascular complications and prevalence of urgency incontinence in Japanese patients with type 2 diabetes mellitus: The Dogo Study. Intern Med 2017;56(8):889-93. DOI: 10.2169/internalmedicine.56.8063
18. Трухан Д.И., Гаврилов А.С., Мазуров А.Л. Коррекция антигипертензивной терапии у пациенток с гиперактивным мочевым пузырем. Международный журнал прикладных и фундаментальных исследований. 2011;(12):34-5. https://elibrary.ru/item.asp?id=17259251
Trukhan D.I., Gavrilov A.S., Mazurov A.L. Correction of antihypertensive therapy in patients with overactive bladder. International Journal of Applied and Fundamental Research. 2011;(12):34-5. https://elibrary.ru /item.asp?id=17259251 (in Russian).
19. Gamé X, Phé V. Pathophysiology of overactive bladder. Prog Urol 2020;30(14):873-79. DOI: 10.1016/j.purol.2020.08.003
20. Трухан Д.И., Викторова И.А. Нефрология. Эндокринология. Гематология. Уч. пособие. СПб: СпецЛит, 2023. https://www.elibrary.ru/ item.asp?id=54271252
Trukhan D.I., Viktorova I.A. Nephrology. Endocrinology. Hematology. A study guide. Saint Petersburg: SpetsLit, 2023. https://www.elibrary.ru/ item.asp?id=54271252 (in Russian).
21. Клинические рекомендации. Недержание мочи. Минздрав России. 2020. https://cr.minzdrav.gov.ru/recomend/8_1
Clinical recommendations. Urinary incontinence. The Ministry of Health of Russia. 2020. https://cr.minzdrav.gov.ru/recomend/8_1 (in Russian).
22. Трухан Д.И., Юренев Г.Л., Макушин Д.Г., Чусова Н.А. Симптомы нижних мочевых путей: дифференциальный диагноз на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019;(3):23-8. https://elibrary.ru/item.asp?id= 41351801
Trukhan D.I., Yurenev G.L., Makushin D.G., Chusova N.A. Symptoms of the lower urinary tract: differential diagnosis at the stage of primary health care. The directory of the polyclinic doctor. 2019;(3):23-8. https://elibrary.ru/ item.asp?id=41351801 (in Russian).
23. Nambiar AK, Bosch R, Cruz F et al. EAU Guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 2018;73(4):596-609. DOI: 10.1016/j.eururo.2017.12.031
24. Gacci M, Sakalis VI, Karavitakis M et al. European Association of Urology guidelines on male urinary incontinence. Eur Urol 2022;82(4):387-98. DOI: 10.1016/j.eururo.2022.05.012
25. Трухан Д.И., Филимонов С.Н. Заболевания почек и мочевых путей. Новокузнецк, 2024. https://www.elibrary.ru/item.asp?id=69184432
Trukhan D.I., Filimonov S.N. Diseases of the kidneys and urinary tract. Novokuznetsk, 2024. https://www.elibrary.ru/item.asp?id=69184432 (in Russian).
26. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedebergs Arch Pharmacol 2002;366(2):97-103. DOI: 10.1007/s00210-002-0554-x
27. Nelson CP, Gupta P, Napier CM et al. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004;310(3):1255-65. DOI: 10.1124/jpet.104.067140
28. Bhide AA, Digesu GA, Swift S. Overactive bladder medication – do we need to revisit trospium chloride for our elderly patients? Int Urogynecol J 2023;34(5):961-62. DOI: 10.1007/s00192-023-05559-5
29. Alkis O, Ozlu A, Kartal IG et al. How effectively do we apply first-line treatment in overactive bladder? Int Urogynecol J 2022;(33):2299-306. DOI: 10.1007/s00192-022-05279-2
30. Duong V, Iwamoto A, Pennycuff J et al. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J 2021;(32):2693-702. DOI: 10.1007/s00192-021-04909-5
31. Dmochowski RR, Thai S, Iglay K et al. Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis. Neurourol Urodyn 2021;40(1):28-37. DOI: 10.1002/nau.24536
32. Araklitis G, Robinson D, Cardozo L. Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging 2020;(15):1493-503. DOI: 10.2147/CIA.S252852
33. Menhaji K, Cardenas-Trowers OO, Chang OH et al. Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. Int Urogynecol J 2021;(32):2819-26. DOI: 10.1007/s00192-021-04736-8
34. Alhasso A, Glazener CM, Pickard R, N’dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005;2005(3): CD001842. DOI: 10.1002/14651858.CD001842.pub2
35. Kennelly MJ, Rhodes T, Girman CJ et al. Efficacy of vibegron and mirabegron for overactive bladder: A systematic literature review and indirect treatment comparison. Adv Ther 2021;38(11):5452-64. DOI: 10.1007/s12325-021-01902-8
36. Staskin D, Frankel J, Varano S et al. Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol 2021;205(5):1421-29. DOI: 10.1097/JU.0000000000001574
37. Wang J, Zhou Z, Cui Y et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn 2019;38(1):22-30. DOI: 10.1002/nau.23863
38. Sebastianelli A, Russo GI, Kaplan SA et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol 2018;25(3): 196-205. DOI: 10.1111/iju.13498
39. Коршунова Е.С., Коршунов М.Н., Нужный Е.П. и др. Нейрогенный гиперактивный мочевой пузырь: фокус на когнитивную функцию. Урология. 2021;(5):35-40. DOI: 10.18565/urology.2021.5.35-40
Korshunova E.S., Korshunov M.N., Nuzhny E.P., etc. Neurogenic overactive bladder: focus on cognitive function. Urology. 2021;(5):35-40. DOI: 10.18565/urology.2021.5.35-40 (in Russian).
40. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005;44(7):701-20. DOI: 10.2165/00003088-200544070-00003
41. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009;43(2):283-95. DOI: 10.1345/aph.1L160
42. Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 2012;18(2):167-74. DOI: 10.1111/j.1755-5949.2011.00248.x
43. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27(2):144-53. DOI: 10.1016/j.clinthera.2005.02.014
44. Buser N, Ivic S, Kessler TM et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analyses. Eur Urol 2012;62(6):1040-60. DOI: 10.1016/j.eururo.2012.08.060
45. Madersbacher H, Rovner E. Trospium chloride: The European experience. Expert Opin Pharmacother 2006;7(10):1373-80. DOI: 10.1517/14656566.7.10. 1373
46. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010;58(8):1618-19. DOI: 10.1111/j.1532-5415.2010.02988.x
47. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64(9):1294-300. DOI: 10.1111/j.1742-1241.2010.02433.x
48. Wiedemann A, Anding R, Kirschner-Hermanns R. Characteristics of urinary incontinence in the elderly. Urologe A 2014;53(10):1543-50. DOI: 10.1007/s00120-014-3608-z
49. Kerdraon J, Robain G, Jeandel C et al.; Groupe de recherche appliquée à la pelvi-périnéologie de la personne âgée (GRAPPPA). Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol 2014;24(11):672-81. DOI: 10.1016/j.purol.2014.06.003
50. Bexten M, Oswald S, Grube M et al. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm 2015;12(1):171-78. DOI: 10.1021/mp 500532x
51. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract 2010;64(11):1535-40.
52. Kranz J, Petzinger E, Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol 2013;31(1):219-24. DOI: 10.1007/s00345-011-0803-z
53. Staskin DR. Overactive bladder in the elderly: A guide to pharmacological management. Drugs Aging 2005;22(12):1013-28. DOI: 10.2165/00002512-200522120-00003
54. Notz HJ, Hautumm B, Werdier D et al. Trospium chloride once daily for overactive bladder syndrome: results of a multicenter observational study. Urologe A 2013;52(1):65-70. DOI: 10.1007/s00120-012-2989-0
55. Geoffrion R; Urogynaecology Committee. Treatments for overactive bladder: Focus on pharmacotherapy. J Obstet Gynaecol Can 2012;34(11):1092-101. DOI: 10.1016/S1701-2163(16)35440-8
56. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;(1):120-5. DOI: 10.18565/urology.2021.1.120-125
Kulchavenya E.V., Holtobin D.P. Hyperactive bladder in a difficult patient: which drug should I choose? Urology. 2021;(1):120-5. DOI: 10.18565/urology.2021.1.120-125 (in Russian).
57. Школьников М.Е., Кривобородов Г.Г., Ефремов Н.С. Троспия хлорид (спазмекс) в лечении больных гиперактивным мочевым пузырем. Consilium Medicum. 2011;(7):16-8. https://www.elibrary.ru/item.asp? id=20226027
Shkolnikov M.E., Krivoborodov G.G., Efremov N.S. Trospium chloride (spasmex) in the treatment of patients with overactive bladder. Consilium Medicum. 2011;(7):16-8. https://www.elibrary.ru/item.asp?id=20226027 (in Russian).
58. Данилов В.В., Вольных И.Ю. Обоснование назначения троспия хлорида в первой линии терапии при гиперактивном мочевом пузыре. Фарматека. 2023;(1-2):226-31. DOI: 10.18565/pharmateca.2023.1-2.226-230
Danilov V.V., Volnykh I.Yu. Justification of the appointment of trospium chloride in the first line of therapy for overactive bladder. Pharmateca. 2023;(1-2):226-31. DOI: 10.18565/pharmateca.2023.1-2.226-230 (in Russian).
59. Kachru N, Holmes HM, Johnson ML et al. Antimuscarinic use among older adults with dementia and overactive bladder: A Medicare beneficiaries study. Curr Med Res Opin 2021;37(8):1303-13. DOI: 10.1080/03007995.2021. 1920899
60. Котовская Ю.В., Остапенко В.С., Ткачева О.Н. Сохранение когнитивных функций у пациентов пожилого возраста: важность гериатрического подхода. Справочник поликлинического врача. 2017;(5):15-9. https://www.elibrary.ru/item.asp?id=32210910
Kotovskaya Yu.V., Ostapenko V.S., Tkacheva O.N. Preservation of cognitive functions in elderly patients: the importance of the geriatric approach. The directory of the polyclinic doctor. 2017;(5):15-9. https://www.elibrary.ru/ item.asp?id=32210910 (in Russian).
61. Кульчавеня Е.В. Постковидный синдром в урологии. Клинический разбор в общей медицине. 2022;(4):66-72. DOI: 10.47407/kr2022.3.4.00154
Kulchavenya E.V. Postcovid syndrome in urology. Clinical review for general practice 2022;(4):66-72. DOI: 10.47407/kr2022.3.4.00154 (in Russian).
62. Борисов В.В. Значение диагностики и терапии урологических осложнений COVID-нейроинфекции для внутренней медицины. Терапия. 2022;(1):142-51. DOI: 10.18565/therapy.2022.1.142-151
Borisov V.V. The importance of diagnosis and therapy of urological complications of COVID-neuroinfection for internal medicine. Therapy. 2022;(1):142-51. DOI: 10.18565/therapy.2022.1.142-151 (in Russian).
63. Кульчавеня Е.В., Шевченко С.Ю. Влияние вируса SARS-COV-2 на мочевой пузырь. Урология. 2023;(1):41-5. DOI: 10.18565/urology.2023.1.41-45
Kulchavenya E.V., Shevchenko S.Y. The effect of the SARS-COV-2 virus on the bladder. Urology. 2023;(1):41-5. DOI: 10.18565/urology.2023.1.41-45 (in Russian).
64. Lamb LE, Dhar N, Timar R et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses 2020;(145):110375. DOI: 10.1016/j.mehy.2020.110375
65. Трухан Д.И. Новая коронавирусная инфекция (COVID-19) и заболевания/патологические состояния почек и мочевых путей. Клинический разбор в общей медицине. 2022;(1):6-15. DOI: 10.47407/kr2022.3.
1.00111
Trukhan D.I. New coronavirus infection (COVID-19) and diseases/pathological conditions of the kidneys and urinary tract. Clinical review for general practice. 2022;(1):6-15. DOI: 10.47407/kr2022.3.1.00111 (in Russian).
66. Lamb LE, Timar R, Wills M et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephro. 2022;54(1):17-21. DOI: 10.1007/s11255-021-03030-2
67. Кривобородов Г.Г., Тур Е.И., Ефремов Н.С., Школьников М.Е. Высокие дозы троспия хлорида у больных с гиперактивным мочевым пузырем вследствие неврологических заболеваний. Данные мультицентровой наблюдательной программы РЕСУРС. Consilium Medicum. 2015;(12):64-7. https://elibrary.ru/item.asp?id=25338965
Krivoborodov G.G., Tur E.I., Efremov N.S., Shkolnikov M.E. High doses of trospium chloride in patients with overactive bladder due to neurological diseases. The data of the multicenter observation program is a RESOURCE. Consilium Medicum. 2015;(12):64-7. https://elibrary.ru/item.asp?id= 25338965 (in Russian).
68. Кривобородов Г.Г., Тур Е.И., Ефремов Н.С. Троспия хлорид в лечении гиперактивного мочевого пузыря у пациентов пожилого и старческого возраста с неврологическими заболеваниями (данные многоцентровой наблюдательной программы «РЕСУРС»). Consilium Medicum. 2016;(7):55-9. https://elibrary.ru/item.asp?id=27327199
Krivoborodov G.G., Tur E.I., Efremov N.S. Trospium chloride in the treatment of overactive bladder in elderly and senile patients with neurological diseases (data from the multicenter observational program «RESOURCE»). Consilium Medicum. 2016;(7):55-9. https://elibrary.ru/item.asp?id= 27327199 (in Russian).
69. Кривобородов Г.Г., Тур Е.И., Ефремов Н.С., Школьников М.Е. Высокие дозы троспия хлорида у больных с идиопатическим гиперактивным мочевым пузырем. Данные мультицентровой масштабной наблюдательной программы «РЕСУРС». Урология. 2016;(4):29-34. https://www .elibrary.ru/item.asp?id=27390767
Krivoborodov G.G., Tur E.I., Efremov N.S., Shkolnikov M.E. High doses of trospium chloride in patients with idiopathic overactive bladder. Data from the multicenter large-scale observation program «RESOURCE». Urology. 2016;(4):29-34. https://www.elibrary.ru/item.asp?id=27390767 (in Russian).
70. Школьников М.Е., Кривобородов Г.Г., Лучинский С.А. и др. Роль троспия хлорида в лечении женщин с синдромом гиперактивного мочевого пузыря. Гинекология. 2012;(4):83-6. https://elibrary.ru/item.asp?id= 17962101
Shkolnikov M.E., Krivoborodov G.G., Luchinsky S.A. et al. The role of trospium chloride in the treatment of women with overactive bladder syndrome. Gynecology. 2012;(4):83-6. https://elibrary.ru/item.asp?id=17962101 (in Russian).
71. Школьников М.Е., Кривобородов Г.Г., Лучинский С.А. и др. Новые тенденции фармакотерапии женщин с синдромом гиперактивного мочевого пузыря. Фарматека. 2012;(12):31-5. https://elibrary.ru/item.asp? id=18246748
Shkolnikov M.E., Krivoborodov G.G., Luchinsky S.A. et al. New trends in pharmacotherapy for women with overactive bladder syndrome. Pharmateca. 2012;(12):31-5. https://elibrary.ru/item.asp?id=18246748 (in Russian).
72. Данилов В.В., Вольных И.Ю., Данилов Вал.В., Данилов Вит.В. Вопросы назначения М-холинолитиков после операции синтетического слинга у женщин. Consilium Medicum. 2017;(7):45-9. https://www.elibrary.ru/ item.asp?id=30311165
Danilov V.V., Volnykh I.Yu., Danilov V.V., Danilov V.V. Issues of prescribing M-cholinolytics after synthetic sling surgery in women. Consilium Medicum. 2017;(7):45-9. https://www.elibrary.ru/item.asp?id=30311165 (in Russian).
73. Geller EJ, Dumond JB, Bowling JM et al. Effect of trospium chloride on cognitive function in women aged 50 and older: A randomized trial. Female Pelvic Med Reconstr Surg 2017;23(2):118-23. DOI: 10.1097/SPV. 0000000000000374
74. Ильина И.Ю., Доброхотова Ю.Э., Чикишева А.А. и др. Расстройства мочеиспускания после родов: методы коррекции. Consilium Medicum. 2018;(6):66-9. DOI: 10.26442/2075-1753_2018.6.66-69
Ilyina I.Yu., Dobrokhotova Yu.E., Chikisheva A.A. et al. Urinary disorders after childbirth: methods of correction. Consilium Medicum. 2018;(6):66-9. DOI: 10.26442/2075-1753_2018.6.66-69 (in Russian).
75. Данилов В.В., Вольных И.Ю., Севрюков Ф.А. и др. Объективизация изменений уродинамики нижних мочевых путей при назначении М-холинолитиков у женщин с недержанием мочи. Фарматека. 2024;(6):201-6. DOI: 10.18565/pharmateca.2024.6.201-206
Danilov V.V., Volnykh I.Yu., Sevryukov F.A. et al. Objectification of changes in the urodynamics of the lower urinary tract when prescribing M-cholinolytics in women with urinary incontinence. Pharmateca. 2024;(6):201-6. DOI: 10.18565/pharmateca.2024.6.201-206 (in Russian).
76. MacDiarmid SA, Ellsworth PI, Ginsberg DA et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology. 2011;77(1):24-9. DOI: 10.1016/j.urology.2010.07.469.77
77. Школьников М.Е., Кривобородов Г.Г., Ефремов Н.С. Роль троспия хлорида (Спазмекс) в лечении мужчин с симптомами гиперактивного мочевого пузыря и аденомой предстательной железы. Consilium Medicum. 2012;(7):43-6.
Shkolnikov M.E., Krivoborodov G.G., Efremov N.S. The role of trospium chloride (Spasmex) in the treatment of men with symptoms of an overactive bladder and prostate adenoma. Consilium Medicum. 2012;(7):43-6. (in Russian).
78. Кульчавеня Е.В., Брижатюк Е.В., Бреусов А.А. Гиперактивный мочевой пузырь как маска хронического простатита. Урология. 2012;(6):43-6. https://elibrary.ru/item.asp?id=18225241
Kulchavenya E.V., Brizhatyuk E.V., Breusov A.A. Hyperactive bladder as a mask of chronic prostatitis. Urology. 2012;(6):43-6. https://elibrary.ru /item.asp?id=18225241 (in Russian).
79. Глыбочко П.В., Аляев Ю.Г., Винаров А.З. и др. Применение М-холиноблокаторов в комплексном лечении недержания мочи после радикальной простатэктомии. Фарматека. 2013;(3):57-60. https://www. elibrary.ru/item.asp?id=18911759
Glybochko P.V., Alyaev Yu.G., Vinarov A.Z. et al. The use of M-holinoblockers in the complex treatment of urinary incontinence after radical prostatectomy. Pharmateca. 2013;(3):57-60. https://www.elibrary.ru/item.asp? id=18911759 (in Russian).
80. Yan M, Xue P, Wang K et al. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? A prospective, randomized, controlled trial. Strahlenther Onkol 2017;193(9):714-21. DOI: 10.1007/s00066-017-1162-5
81. Kosilov K, Loparev S, Kuzina I et al. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male 2017;20(1):39-44. DOI: 10.1080/13685538.2016.1247435
82. Коровина Н.А., Захарова И.Н., Мумладзе Э.Б. и др. Современные подходы к лечению инфекции мочевой системы у детей. Педиатрия. Прил. к журн. Consilium Medicum. 2004;(1):33-8. https://www. elibrary.ru/item.asp?id=21090899
Korovina N.A., Zakharova I.N., Mumladze E.B. et al. Modern approaches to the treatment of urinary tract infections in children. Pediatrics. Adj. to the Journal. Consilium Medicum. 2004;(1):33-8. https://www. elibrary.ru/item.asp?id=21090899 (in Russian).
83. Осипов И.Б., Лебедев Д.А. Эффективность применения препарата «Спазмекс» при нестабильном мочевом пузыре у детей. Педиатр. 2004;(2):48-53. https://www.elibrary.ru/item.asp?id=21463184
Osipov I.B., Lebedev D.A. The effectiveness of the drug «Spasmex» in unstable bladder in children. Pediatrician. 2004;(2):48-53. https://www.elibrary.ru/item.asp?id=21463184 (in Russian).
84. Новожилов Е.В., Яновой В.В., Малаев А.А., Завгородний В.Н. Неинвазивный уродинамический мониторинг в оценке эффективности консервативного лечения гиперактивного мочевого пузыря у детей. Дальневосточный медицинский журнал. 2009;(3):58-60. https://www.elibrary.ru/item.asp?id=13052092
Novozhilov E.V., Yanova V.V., Malaev A.A., Zavgorodny V.N. Noninvasive urodynamic monitoring in evaluating the effectiveness of conservative treatment of overactive bladder in children. Far Eastern Medical Journal. 2009;(3):58-60. https://www.elibrary.ru/item.asp?id=13052092 (in Russian).
85. Fahmy A, Youssif M, Rhashad H et al. Combined low-dose antimuscarinics for refractory detrusor overactivity in children. J Pediatr Urol 2016;12(4):219.e1-5. DOI: 10.1016/j.jpurol.2016.04.023
For citation:Trukhan D.I., Kalinichenko D.A. Urinary incontinence: focus on overactive bladder. Topical aspects of clinical features, diagnosis, and treatment at the outpatient stage. Clinical review for general practice. 2025; 6 (1): 50–60 (In Russ.). DOI: 10.47407/kr2024.6.01.00p543
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
